TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22640563
Drug: Fluticasone inhalation
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone inhalation (250 μg twice daily)
Study: 22640563
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (1mg/kg once daily)
Study: 22640563
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation (room air twice daily)
Study: 20535764
Drug: Assigned treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assigned treatment for migraine
Study: 20535764
Drug: Assigned treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assigned treatment for other chronic diseases
Study: 18853660
Drug: Chemotherapy (Adriamycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Adriamycin, Vincristin, Cyclophosphamide) + Radiation (40 Gy)
Study: 11169943
Drug: Paclitaxel, 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel, 175 mg/m(2) intravenously over 3 hours on Day 1, followed by leucovorin, 300 mg over 30-60 minutes and 5-fluorouracil, 350 mg/m(2) intravenously on Days 1-3 (Arm A)
Study: 11169943
Drug: Etoposide, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide, 100 mg/m(2) intravenously on Days 1-3 and carboplatin at an area under the curve of 6 on Day 1 (Arm B)
Study: 9391858
Drug: Successful recanalization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful recanalization therapy after AMI
Study: 8198723
Drug: Silastic Gel
Normalized name: CATHETER SILASTIC 14FR 5CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silastic Gel Sheeting (SGS)
Study: 8198723
Drug: Cica-Care (CC)
Normalized name: DRESSING,CICA-CARE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cica-Care (CC)
Study: 3109227
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (control group with no treatment)
Study: 25999707
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg twice daily for one year in the extremely slow/slow EPHX1 enzyme activity group
Study: 25999707
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg twice daily for one year in the fast/normal EPHX1 enzyme activity group
Study: 16495262
Drug: Oritavancin 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oritavancin 5 mg/kg/day
Study: 16495262
Drug: Oritavancin 6.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oritavancin 6.5 mg/kg/day
Study: 16495262
Drug: Oritavancin 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oritavancin 8 mg/kg/day
Study: 16495262
Drug: Oritavancin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oritavancin 10 mg/kg/day
Study: 11151876
Drug: Mesalazine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine therapy for 8 weeks
Study: 11151876
Drug: Mesalazine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine therapy
Study: 9174316
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg 5% meperidine alone
Study: 27198129
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (LOW) with hemoglobin trigger of 7 g/dL
Study: 27198129
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (HIGH) with hemoglobin trigger of 8 g/dL
Study: 25555523
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no TENS treatment)
Study: 23733779
Drug: FAC-wP (Fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC-wP (Fluorouracil, Doxorubicin, Cyclophosphamide followed by weekly Paclitaxel)
Study: 20492852
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) + SSRI
Study: 9108847
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine combined with oral poliovirus vaccine
Study: 9108847
Drug: MRC‐5 cell‐derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRC‐5 cell‐derived inactivated poliovirus vaccine as a combined injection
Study: 9108847
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated poliovirus vaccine
Study: 9108847
Drug: Inactivated poliovirus
Normalized name: Inactivated poliovirus type I
DrugBank: Poliovirus type 1 antigen (formaldehyde inactivated) (DB10795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated poliovirus vaccine (MRC‐5 or Vero cell-derived)
Study: 4035330
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of amitriptyline (AT) per day
Study: 4035330
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of amitriptyline (AT) per day
Study: 31352795
Drug: Simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 80 mg via nasogastric tube after declaration of brain death
Study: 31352795
Drug: No simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No simvastatin treatment
Study: 27908347
Drug: NT-proBNP reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP reduction to ≤1,000 pg/ml
Study: 19075279
Drug: GLSG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLSG treatment (1996 to 2004)
Study: 19075279
Drug: KLSG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: KLSG treatment (1975 to 1986)
Study: 15840776
Drug: Professionally applied
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professionally applied fluoride gel (1% sodium fluoride, applied semi-annually)
Study: 12588354
Drug: Short and
Normalized name: ALLERGENIC EXTRACT,RAGWEED,SHORT AND TALL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short and intensive chemotherapy (most recent protocol)
Study: 12588354
Drug: Previous trials
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous trials (less intensive chemotherapy)
Study: 12588354
Drug: LDH >=
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDH >= 500 IU/l
Study: 12588354
Drug: LDH <
Normalized name: Lactate dehydrogenase
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDH < 500 IU/l
Study: 10507207
Drug: 30% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% hydrogen peroxide solution
Study: 8594265
Drug: Intravenous T(3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous T(3) (0.8 microg/kg followed by 0.12 microg.kg(‐1).h(‐1) for 6 hours)
Study: 1768545
Drug: Buprenorphine 0.2
Normalized name: buprenorphine 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 0.2 mg sublingually
Study: 6803191
Drug: Continuous nasogastric
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nasogastric feedings with phenytoin suspension 300 mg per day
Study: 6803191
Drug: Continuous tube
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous tube feedings started with phenytoin suspension 300 mg per day
Study: 6803191
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of phenytoin suspension alone
Study: 24345827
Drug: Isocaloric placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric placebo comparison supplement
Study: 16055263
Drug: Paroxetine medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine medication for 8 weeks
Study: 7589764
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg dihydroergocristine
Study: 7589764
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg dihydroergocristine
Study: 2297463
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg BN 52063 p.o.
Study: 2297463
Drug: 2.4 mg
Normalized name: pectin 2.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 mg BN 52063 inhalation
Study: 2297463
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg BN 52063 p.o. (EIA study)
Study: 2297463
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg BN 52063 inhalation (EIA study)
Study: 6971551
Drug: Ergocalciferol 5000
Normalized name: ERGOCALCIFEROL 50000UNT TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergocalciferol 5000 units daily
Study: 31200775
Drug: Vibrotactile stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibrotactile stimulation (gentle mechanical vibrations administered during 3 h at night for 3 weeks)
Study: 25867798
Drug: Triple-dose Gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-dose Gadolinium (TdGd) administration
Study: 25867798
Drug: Less frequent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less frequent gadolinium administration
Study: 24112999
Drug: Venlafaxine IR,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine IR, 150 mg
Study: 21377076
Drug: PCA group
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA group with continuous background morphine infusion (Group 2; n = 30)
Study: 21377076
Drug: PCA group
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA group without continuous background morphine infusion (Group 1; n = 30)
Study: 19289979
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment by community health workers (CHWs) using injectable antibiotics for very severe disease.
Study: 19289979
Drug: Treatment by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by qualified medical providers.
Study: 19289979
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment or treatment by unqualified providers.
Study: 19289979
Drug: Home treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home treatment by CHWs compared to no treatment/untrained providers.
Study: 19289979
Drug: Treatment by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by qualified providers compared to no treatment/untrained providers.
Study: 18065585
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (3 g/d, 1.8 g n-3 PUFAs)
Study: 15367054
Drug: Relaxation/massage therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation/massage therapy
Study: 15367054
Drug: Infant-mother relationship
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant-mother relationship therapy
Study: 10706235
Drug: Kudzu root
Normalized name: kudzu root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kudzu root extract 1.2 g twice daily
Study: 9305414
Drug: Ritanserin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin 2.5 mg
Study: 9305414
Drug: Ritanserin (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (both doses)
Study: 1467416
Drug: Trometamol Phosphomicine
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trometamol Phosphomicine (TP) - single oral dose
Study: 1467416
Drug: Pipemidic Acid
Normalized name: pipemidic acid
DrugBank: Pipemidic acid (DB13823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipemidic Acid (PA) - 400 mg twice a day for 5 to 7 days
Study: 1467416
Drug: Norfloxacine (NFX)
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacine (NFX) - 400 mg twice a day for 5 to 7 days
Study: 1424409
Drug: Placebo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after 50 mg atenolol daily
Study: 22492697
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (cisplatin 100 mg/m² day 1 + 5-FU 1000 mg/m² day 1-5) followed by irradiation for complete responders
Study: 21235067
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (Lactulose, 20-30 mL/d)
Study: 16873930
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - Prempo (0.625 mg conjugated estrogen and 2.5 mg medroxyprogesterone acetate)
Study: 12845587
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of stavudine (40 mg)
Study: 12845587
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of stavudine (40 mg)
Study: 8876577
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of bupivacaine hydrochloride for 72 hours postoperatively
Study: 8876577
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution for 72 hours postoperatively (Control Group)
Study: 8876577
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of bupivacaine hydrochloride
Study: 28230252
Drug: Ganaxolone 1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganaxolone 1,500 mg/day
Study: 19441604
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate and salmeterol combination via hydrofluoroalkane metered-dose inhaler
Study: 19441604
Drug: Placebo via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo via traditional chlorofluorocarbon metered-dose inhaler
Study: 1706903
Drug: i.m. injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. injection of 0.5 ml 'Influmun' vaccine from SSW Dresden/GDR
Study: 1706903
Drug: enteric-wated capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: enteric-wated capsules containing approximately 60 micrograms hemagglutinin of all three virus strains
Study: 86665
Drug: surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: surgical treatment
Study: 28691550
Drug: Exposure and
Normalized name: Anthrax vaccine, adsorbed, pre-exposure and post-exposure prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure and response prevention (ERP) therapy for OCD, 4 weeks duration
Study: 27780630
Drug: Tdap administered
Normalized name: acellular pertussis vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap administered 3-4 weeks before PCV13 and MCV4 (Group A)
Study: 27780630
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three vaccines administered on the same day (Group B)
Study: 27780630
Drug: PCV13 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV13 and MCV4 administered 3-4 weeks before Tdap (Group C)
Study: 10394962
Drug: Ifosfamide (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide (1,500 mg/m2 over 5 days intravenously)
Study: 10394962
Drug: Temozolomide (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (100-200 mg/m2 over 5 days orally)
Study: 2148150
Drug: Verapamil 120
Normalized name: verapamil 120 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 120 mg three times daily for 4 weeks
Study: 31342823
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality distraction during dressing change plus standard pharmacological analgesic intervention
Study: 31342823
Drug: Standard pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacological analgesic intervention during dressing change
Study: 23388358
Drug: Modified WHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified WHO hand rub formulations with higher alcohol concentration (5% increase) and lower glycerol concentration (0.725%)
Study: 23388358
Drug: Modified WHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified WHO hand rub formulations without glycerol
Study: 20980992
Drug: Oxycodone (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (0, 10, 20, 40, and 60 mg/70 kg)
Study: 20980992
Drug: Sublingual buprenorphine/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine/naloxone (Bup/Nx; 2/0.5, 8/2, and 16/4 mg/day)
Study: 17103296
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of resistance and balance-jumping training (COMB)
Study: 17103296
Drug: Training at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training at least twice a week in COMB group
Study: 10858838
Drug: Midazolam coinduction
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam coinduction (0.05 mg/kg BW midazolam, 2.5 micrograms/kg BW fentanyl, 1.0 mg/kg BW propofol)
Study: 10858838
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2.5 micrograms/kg BW fentanyl and 2.0 mg/kg BW propofol)
Study: 9350069
Drug: Moderately salt-restricted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately salt-restricted diet (5 capsules of placebo)
Study: 9350069
Drug: Salt-supplemented group
Normalized name: potassium chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salt-supplemented group (5 capsules of 10 mmol sodium per capsule)
Study: 8462079
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (3.15 g omega-3 fatty acids)
Study: 29617940
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) access
Study: 27655438
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg vitamin D3 supplements/d for 20 weeks
Study: 27655438
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg vitamin D3 supplements/d for 20 weeks
Study: 27655438
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 μg vitamin D3 supplements/d for 20 weeks)
Study: 27655438
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D intake to maintain 25(OH)D concentrations >25 nmol/L
Study: 27655438
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D intake to maintain 25(OH)D concentrations >30 nmol/L
Study: 27655438
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D intake to maintain 25(OH)D concentrations >40 nmol/L
Study: 27655438
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D intake to maintain 25(OH)D concentrations >50 nmol/L
Study: 20041414
Drug: Blackcurrant oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blackcurrant oil soft capsule (BOSC) 1.8 g b.i.d. every day for 6 weeks
Study: 20041414
Drug: Blackcurrant oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blackcurrant oil soft capsule (BOSC)
Study: 19143245
Drug: Periarticular intraoperative
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular intraoperative injection of multimodal analgesic drugs
Study: 12415026
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment 0.1 IU/kg/d subcutaneously at bedtime for 2 months
Study: 12415026
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 2 months
Study: 10754618
Drug: Clevidipine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevidipine 20 min infusion
Study: 10754618
Drug: Clevidipine 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevidipine 24 h infusion
Study: 8771866
Drug: beta‐1,3‐D‐glucan gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta‐1,3‐D‐glucan gel
Study: 1474987
Drug: Fenticonazole powder
Normalized name: fenticonazole
DrugBank: Fenticonazole (DB13434)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenticonazole powder (antifungal treatment)
Study: 6726012
Drug: HLI (Human
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLI (Human leukocyte interferon) ophthalmic drops (2.4 x 10^6 IU/ml, 50,000 units per drop, administered two times a day for five days)
Study: 6726012
Drug: Placebo (commercial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (commercial artificial tear solution)
Study: 26064048
Drug: AOM 400
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AOM 400 (400 mg once-monthly)
Study: 26064048
Drug: Oral aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral aripiprazole (10-30 mg/d)
Study: 26064048
Drug: AOM 50
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AOM 50 mg (subtherapeutic dose)
Study: 21456040
Drug: DBT-enhanced habit
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBT-enhanced habit reversal treatment (HRT)
Study: 16453051
Drug: Oral crystalline
Normalized name: Mesembryanthemum crystallinum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral crystalline cyanocobalamin (1,000 microgram per day for at least 1 month)
Study: 12910570
Drug: Glucosamine (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine (alone and in combination with chondroitin)
Study: 11502782
Drug: 2 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/d oral L-carnitine
Study: 11502782
Drug: 4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/d oral L-carnitine
Study: 9422900
Drug: Prone knee‐chest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prone knee‐chest position with 3 ml of 0.5% bupivacaine